BIRC5 and cancer: Survivin (also known as BIRC5) has been a well-known cancer therapeutic target since its discovery over 20 years ago.267 Because of its essential role in cell mitosis and inhibition of apoptosis,268–270 as well as its variable expression levels in cancer and normal cells,271 survivin appears be a ideal candidate for anticancer therapy.